Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The pursuit, or "hunt", for new drugs is the core mission of our company. Founded in 2010, Venatorx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs.
Venatorx has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA); and CARB-X, and as well as private equity investments from Versant Ventures, Abingworth and Foresite Capital.
Venatorx has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Service (HHS); the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA); and CARB-X, and as well as private equity investments from Versant Ventures, Abingworth and Foresite Capital.
Services
Venatorx Pharmaceuticals (the "Company") is focused on conducting clinical studies and obtaining regulatory approval of investigational medicines in support of its mission to develop safe and effective treatments for infectious diseases. The best way for patients to get access to investigational medicines is by taking part in clinical trials.
The Next-Generation -Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli. Gram-negative bacteria producing carbapenemases are resistant to a variety of -lactam antibiotics and pose a significant health risk.
Given the dearth of new antibiotics, combinations of new broad-spectrum -lactamase inhibitors (BLIs) with approved -lactams have provided treatment options for resistant bacterial infections.Taniborbactam (formerly VNRX-5133) is an investigational BLI that is effective against both serine- and metallo--lactamases, including the serine carbapenemase KPC.
Given the dearth of new antibiotics, combinations of new broad-spectrum -lactamase inhibitors (BLIs) with approved -lactams have provided treatment options for resistant bacterial infections.Taniborbactam (formerly VNRX-5133) is an investigational BLI that is effective against both serine- and metallo--lactamases, including the serine carbapenemase KPC.
Venatorx Pharmaceuticals announced a comprehensive update about cefepime-taniborbactam, the Company's intravenous beta-lactam / beta-lactamase inhibitor (BL/BLI) combination antibiotic that is being developed for the treatment of complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Innovation is at the heart of our mission and our people are our greatest asset. We strive to empower our team through trust, loyalty and transparency to provide the tools they need to successfully fulfill their roles and responsibilities and perform at the highest levels. Everyone is valued at Venatorx and has a significant role to play in our future success.
Reviews
Be the first to review VenatoRX.
Write a Review
